**#FDAApproval**

Exciting news for PharmaEngine Inc (4162.TWO)! FDA approves #Onivyde® as a first-line therapy for metastatic pancreatic adenocarcinoma, marking a potential new standard of care.

PharmaEngine's collaborative effort with Ipsen led to this milestone, expanding Onivyde's usage beyond its initial approval in 2015. The FDA's decision follows the Phase III NAPOLI 3 clinical trial, where the Onivyde® regimen demonstrated significant improvements in overall survival and progression-free survival compared to existing therapies.

Read more about this groundbreaking approval: https://lnkd.in/g9DkYRZY

Join #Globalbio for more updates!